• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Dao-Haddock Quyen Thi

    11/18/22 8:22:42 PM ET
    $BIOC
    Medical Specialities
    Health Care
    Get the next $BIOC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    DAO-HADDOCK QUYEN THI

    (Last) (First) (Middle)
    C/O BIOCEPT, INC.
    9955 MESA RIM ROAD

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/17/2022
    3. Issuer Name and Ticker or Trading Symbol
    BIOCEPT INC [ BIOC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities owned
    No securities are beneficially owned.
    /s/ Quyen Thi Dao-Haddock 11/17/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BIOC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOC
    Financials

    Live finance-specific insights

    See more
    • Biocept to Hold Business Update Conference Call on August 30, 2023

      Biocept, Inc. (NASDAQ:BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. The conference call can be accessed at the time of the live call by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international callers.

      8/25/23 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Reports First Quarter 2023 Financial Results

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update. "I'm exceptionally pleased with the progress being made with our FORESEE clinical trial, which is specifically designed to generate evidence of CNSide™'s clinical utility to support adoption into clinical care guidelines and further broaden physician use. Trial enrollment is running well in line with our plan, and we've now activated clinical sites in Dallas, Los Angeles and the San Francisco Bay Area," said Samuel D. Riccitelli, Biocept's Chairman, and interim President and CEO. "In our q

      5/10/23 4:05:00 PM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Reports 2022 Financial Results

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update. "I could not be prouder of my Biocept colleagues as together we have worked tirelessly to streamline operations, prioritize decisions to advance our corporate mission and carefully manage expenditures. We are more convinced than ever that our proprietary CNSide™ assay will improve the lives of patients with cancers that have metastasized to the central nervous system. To support this conviction, we have completed our evaluation of strategic alternatives and determined that the best course

      4/17/23 4:10:00 PM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. "Completing enrollment in this first phase of our FORESEE trial, and doing so ahead of our inte

      9/21/23 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (NASDAQ:PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal metastases (LM), which is cancer in the membranes that surround the brain and spinal cord. CNSide is Biocept's proprietary cerebrospinal fluid (CSF)-based tumor cell capture and enumeration p

      9/8/23 8:00:00 AM ET
      $BIOC
      $PSTV
      Medical Specialities
      Health Care
      Medical/Dental Instruments
    • Biocept to Participate in the H.C. Wainwright Global Investment Conference

      Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the Events & Presentation section of the Company's website beginning Monday, September 11 at 7:00 a.m. Eastern time. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. About Biocept

      9/5/23 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    Leadership Updates

    Live Leadership Updates

    See more
    • Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. "Completing enrollment in this first phase of our FORESEE trial, and doing so ahead of our inte

      9/21/23 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Names Antonino Morales as President and Chief Executive Officer

      Samuel D. Riccitelli resigns as interim President and CEO, and Director Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and Chief Executive Officer, effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as the Company's principal accounting officer. These changes follow the resignation of Samuel D. Riccitelli as interim President and Chief Executive Officer,

      6/20/23 4:15:00 PM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms. Dao-Haddock is a certified public accountant (CPA) with more than 20 years of financial and accounting experience. She will serve on Biocept's Audit Committee. "Quyen's extensive financial experience leading accounting and finance departments, and overseeing technical accounting, budgeting and forecasting, financial modeling, cash management and SEC reporting, make her a valuable addition to our Board and its Audit Committee," said Samuel D. Riccitelli

      11/18/22 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    SEC Filings

    See more
    • Biocept Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BIOCEPT INC (0001044378) (Filer)

      10/20/23 6:06:21 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

      8-K - BIOCEPT INC (0001044378) (Filer)

      10/16/23 8:53:52 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIOCEPT INC (0001044378) (Filer)

      8/22/23 4:10:54 PM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Biocept Inc.

      SC 13G - BIOCEPT INC (0001044378) (Subject)

      6/2/23 4:26:13 PM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Walsh Robert

      3 - BIOCEPT INC (0001044378) (Issuer)

      6/20/23 7:09:58 PM ET
      $BIOC
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Dao-Haddock Quyen Thi

      4 - BIOCEPT INC (0001044378) (Issuer)

      11/18/22 8:26:29 PM ET
      $BIOC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Dao-Haddock Quyen Thi

      3 - BIOCEPT INC (0001044378) (Issuer)

      11/18/22 8:22:42 PM ET
      $BIOC
      Medical Specialities
      Health Care